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Information on chromosomal aberrations in cutaneous T cell lymphomas (CTCL), is scarce. In this study,
comparative genomic hybridization (CGH) was used to analyze chromosomal imbalances (CI) in 32 patients with
CTCL. CI were detected in 21 patients (66%). Euchromatic loss (dim) was localized most frequently (416%) at the
chromosomal regions 17p (28%), 13q (25%), 10q (16%), and 6q (19%), and gain of chromatin (enh) at 7 (25%), 8q
(25%), and 17q (16%). The pattern dim6q–enh7–enh8–dim13 was the most frequent combination of CI. The number
of aberrations per tumor sample varied between 0 and 19 and correlated with clinical tumor stages: from none in
stage Ia to 8.75  1.8 (mean  SEM) in stage IVa. CI occurred more frequently in aggressive subtypes (9.33  2.16)
than in indolent (2.88  0.8) subtypes. A high number of CI (X5) was associated with shorter survival. Gain of
chromatin in 8q and loss of 6q and 13q correlated with a signiﬁcantly shorter survival, whereas the most frequently
observed aberrations (loss in 17p and gain in 7) did not inﬂuence the prognosis. In summary, CGH analysis
revealed a characteristic pattern of recurring chromosomal gains and losses in CTCL. The association of the
imbalances with the clinical course of the disease suggests that genes encoded at these loci may inﬂuence tumor
development and progression.
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Primary cutaneous T cell lymphomas (CTCL) are a group of
extranodal non-Hodgkin lymphomas with an annual inci-
dence similar to Hodgkin’s disease (Weinstock and Horm,
1988). They comprise a broad spectrum of malignant
diseases, which are classified from indolent to aggressive
subtypes based on clinical, histological, and immunohisto-
chemical criteria as proposed by the European Organization
for Research and Treatment of Cancer (EORTC) classifica-
tion (Willemze et al, 1997). Accordingly, mycosis fungoides
(MF), CD30þ large-cell lymphoma, and lymphomatoid
papulosis (LP) are indolent forms, and Se´zary syndrome
(SS) and CD30 large-cell lymphomas are aggressive forms.
Over the past decades several studies have analyzed
genetic aberrations in CTCL at the level of chromosome
alterations, candidate regions, and gene mutations (Whit-
taker, 2001). As compared to other neoplastic disorders
including hematological cancers, the information on genetic
aberrations in CTCL is still rather scarce and a consistent
pattern has not been found. Several factors contribute to
this paucity of information, which include the phenotypic
variety of the disease, the difficulties in obtaining substantial
amounts of tumor cells from skin biopsies, and the absence
or rarity of tumor cells in the peripheral blood. In a recent
study with 19 patients with MF and SS (Thangavelu et al,
1997), conventional cytogenetics was applied. The chro-
mosomal losses were localized most frequently to the short
arms of chromosomes 1 and 8. Other frequent losses were
found in chromosomes 2, 10, and 17. The data of this study
largely confirmed the data published previously (Erkman-
Balis and Rappaport, 1974; Edelson et al, 1979; Whang-
Peng et al, 1979; van Vloten et al, 1980; Sole et al, 1994;
Limon et al, 1995). Interestingly, the chromosomal losses in
regions bearing the T cell receptor genes (7p15, 7q32–35,
14q11, 14q32) prominent in other T cell malignancies were
not or only rarely seen in CTCL.
Comparative genomic hybridization (CGH) has extended
cytogenetic information concerning the detection of chro-
mosomal gains and losses with chromosomal resolution in
one experiment. Since no tumor metaphase spreads are
required, non-cultured skin tumor samples including
archived material can be analyzed. The purity of the tumor
material is of critical importance however, as a pre-
dominance of non-neoplastic cells will result in artificial
mosaicism.
Abbreviations: ATL, adult T cell leukemia/lymphoma; CD, cluster
of differentiation; CGH, comparative genomic hybridization; CI,
chromosomal imbalances; CTCL, cutaneous T cell lymphoma;
EORTC, European Organization for Research and Treatment of
Cancer; KM, Kaplan–Meier; LC, large-cell lymphoma; LP, lympho-
matoid papulosis; MF, mycosis fungoides; MST, median survival
time; PCR, polymerase chain reaction; SS, Se´zary syndrome; TCR,
T cell receptor; TNM, tumor, node, metastasis
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Using CGH, Karenko et al (1999) analyzed 11 patients
with CTCL. Chromosomal imbalances were detected in six
of seven SS patients; in four skin biopsies of MF patients,
no aberrations were found. The results showed losses in
chromosomes 10, 13, and 17 and a gain in chromosome 8.
In 34 cases of MF and SS analyzed by CGH, the most
frequent losses involved chromosomes 1p, 17p, 10q/10,
and 19, whereas common gains were detected in chromo-
somes 4, 18, and 17q (Mao et al, 2002).
In a recent study of 64 patients with adult T cell leukemia/
lymphoma (ATL), CGH results were related to the clinical
course of the disease (Tsukasaki et al, 2001). CI were found
more frequently in aggressive than in indolent (early and
advanced) subtypes of ATL, and were associated with a
shorter survival. In particular, gains at 1q, 4q, and 7 oc-
curred more frequently in aggressive disease. Interestingly,
a chromosomal gain of chromosome 7 was marginally asso-
ciated with a good prognosis.
Chromosomal changes may be directly involved in the
pathogenesis of neoplastic disease and thus may give
important insights into the molecular sequences of tumor
growth. In the present study, CGH was performed for tumor
and blood samples of patients with CTCL and related to the
clinical course of the disease.
Results
CGH analysis For the analysis of chromosomal imbal-
ances, comparative genomic hybridization was performed
by hybridizing orange-labeled reference DNA and green-
labeled tumor DNA to normal metaphase spreads.
Chromosomal aberrations (gains or losses) were seen in
21 of 32 patients (66%; Table I, Fig 1). In these 21 patients,
the most frequent aberrations were euchromatic losses
(¼dim) at the chromosomal regions 17p (28%), 13q (25%),
10q (16%), and 6q (19%) and gains of chromatin (¼ enh) of
chromosome 7 (25%), 8q (25%), and 17q11q22 (16%) (Fig
1). No gene amplification was observed.
The number of aberrations per patient sample varied
between 0 and 19, with an average of 4.09  0.9 (mean
 SEM). The mean aberration number per tumor sample
with CI was 6.24  0.9 (mean  SEM).
In the 32 patients, losses of chromosomal material were
observed slightly more often than gains (54% vs 46%). Gain
of chromosome 7 was associated with loss of chromosome
13q in five of 21 patients (cases 2, 7, 11, 13, and 21),
reflecting chromosomal imbalances. Four of these patients
had additional aberrations such as deletions in chromo-
some 6q and partial trisomy of 8q (cases 2, 11, 13, and 21;
Fig 3). One of the patients (case 11) with this pattern (6q, 7,
8q, 13q) was in stage II of the disease, and three patients
(cases 2, 13, and 21) were in tumor stage IV. These three
cases had an additional loss of chromosome 10q.
All patients with aberrations in chromosomes 6, 10, or 13
were in stage IV. In contrast, imbalances in chromosomes 7,
8, or 17 were also found in earlier stages with a longer
MST.
The most common aberration detected was the deletion
of chromosome 17p. This has only been found twice in this
combination mentioned above (imbalances of 6, 7, 8, and
13). In cases affected by deletion of 17p, the average
number of imbalances was 7.9  2.02, whereas other com-
mon chromosome imbalances (6q, 7, 8q, 10q, and 13q)
were significantly higher ranging between 9.1  1.5 and
13.4  2.11.
Correlation of CGH data with the clinical course For the
mean age (66.4  11.7 y) and sex distribution (12 women,
20 men), the patients examined in this study corresponded
to the average characteristics for CTCL as published by the
EORTC (Willemze et al, 1997).
The number of chromosomal aberrations correlated with
clinical tumor stages: none in stage Ia, 0.44  0.33 (mean
 SEM) in stage Ib, 1.0  0.58 in stage IIa, 3.50  1.08 in
stage IIb, 6.0  2.89 in stage IIIb, 9.33  3.76 in stage IVa,
and 8.75  1.75 in stage IVb (Fig 2).
In advanced stages the 5 y survival was lower than in
early stages (10% vs 100%, MST in advanced stages:
34 mo) and the calculated survival rate was significantly
shorter as compared to early stages (p¼ 0.0059; Fig 3a).
In patients with tumor samples with a high number of
CI (X5), 5 y survival was lower than in patients with tumor
samples displaying less than five CI (45% vs 72%, MST
in patients with more than five CI per tumor sample: 26 mo).
The calculated survival rates of patients with CI X5 were
shorter than in patients with less than five CI (p¼ 0.0059;
Fig 3b).
Comparison of indolent and aggressive forms of CTCL
showed that CI occurred more frequently in the aggressive
subtypes (9.33  2.16) than in indolent (2.88  0.8) sub-
types (Fig 4a). In indolent forms of CTCL, the frequency of
losses and gains was similar (51% vs 49%). In aggressive
forms, losses were found more often than gains (61% vs
39%; po0.05; Fig 4b). The calculated 5 y survival rate was
shorter in aggressive than in indolent forms (o5% vs 64%;
estimated MST in aggressive forms: 26 mo) and the KM
survival curves showed a significantly shorter survival
(p¼0.023; Fig 4c).
For the most frequent CI, the estimated survival was
calculated. Patients with loss of chromatin at 6q had a lower
5 y survival (o5% vs 60%, MST in dim 6q: 24 mo). A
significantly shorter survival was calculated in KM curves
(p¼0.0011, Fig 5a). Patients with a gain in chromosome 7
had a shorter 5 y survival (o5% vs 65%, MST in enh 7: 30
mo). No significant difference using the log-rank test was
seen between calculated KM curves for patients with enh 7
and disomy 7 (Fig 5b). Gain of chromatin in 8q was
associated with a shorter calculated 5 y survival (o5% vs
60%, MST in enh 8q: 25 mo) and the KM curves of patients
with enh 8q were shorter (p¼ 0.0048, Fig 5c). Loss in 10q
reduces the estimated 5 y survival (o5% vs 65%, MST for
dim 10q: 25 mo) with a significantly shorter KM curve
(p¼0.0165, Fig 5d). Loss of chromatin in 13q resulted in a
shorter 5 y survival (o5% vs 70%, MST for loss in 13q: 30
mo) and a reduced KM survival (po0.0001, Fig 5e). The
most frequent aberration dim 17p was not associated with
significantly shorter 5 y survival (30% vs 65%, MST for dim
17p: 50 mo vs normal 17p: 70 mo) and the KM curves did
not differ significantly (po0.6709, Fig 5e).
All other CI were found with lower frequencies that did
not allow statistical calculation of the KM curves.
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Table I. Clinical characteristics and CGH results of 32 patients with indolent and aggressive CTCL
No Sex
Age
(y) Diagnosis Stage Survival
Survival
time (mo)
No. of
CI Group Chromosomal gain Chromosomal loss
1 m 75 MF Ib þ 108 0 I
2 f 52 MF Ia þ 13 0 I
3 m 70 MF Ib þ 72 0 I
4 m 60 MF IIa þ 10 0 I
5 f 61 MF Ib þ 51 0 I
6 m 61 MF Ia þ 11 0 I
7 m 24 LCA30þ Ia þ 5 0 I
8 f 83 MF Ib þ 91 0 I
9 m 79 MF Ib þ 16 0 I
10 f 80 MF Ib þ 8 0 I
11 m 61 MF Ib þ 5 0 I
12 m 62 MF IIb þ 5 1 I enh Xp11.2qter
13 m 54 MF IIa þ 40 1 I dim 19p13.3
14 f 90 MF Ib þ 186 2 I dim 17, dim 20q11.2
15 f 51 MF IIb þ 15 2 I enh 8, enh 11q14qter
16 m 78 MF IIa þ 126 2 I dim 17, dim Xp22.1pter
17 m 69 MF Ib þ 14 2 I enh 7 dim Y
18 m 39 LCA30þ IVb 35 3 I enh 1q11q42, enh 7 dim 13
19 m 70 MF IVa 69 3 I enh 18q10qter dim 4q31.3qter,
dim 19p10p13.2
20 m 80 LCA30þ IVb 18 4 I enh 8q23qter,
enh 19q13.2qter,
enh Xq26qter
dim 6q16q22
21 f 62 LCA30þ IVb 7 5 I enh 9, enh 14 dim 4q33qter,
dim 7q32qter, dim 13
22 m 37 MF IIb þ 12 7 I enh 7, enh 8q10qter,
enh 17q10qter
dim 1p34.3p35,
dim 6q14qter,
dim 11q14qter, dim 13
23 m 75 MF IVb 54 9 I enh 3q21q22, enh 9q10q21,
enh 9q33q34,
enh 15q21q26, enh X
dim 9q22, dim 10q22qter,
dim 17p10pter,
dim 20q10qter
24 m 78 LCP30þ IIIb þ 39 11 I enh 2q14pter,
enh 3q13pter, enh 7,
enh 9, enh 12,
enh 17q10qter, enh 21
dim 3q25qter,
dim 15q10q21,
dim 16q22qter,
dim 17p10pter
25 m 53 LCP30þ IVa þ 26 16 I enh 3, enh 5q21pter,
enh 6p21pter, enh 7p21qter,
enh 8q22qter,
enh 10p10pter;
enh 14q23qter,
enh Xq26qter
dim 5q21qter,
dim 6p21q21, dim 6q24qter,
dim 9p23q22,
dim 10q23qter,
dim 12p12pter, dim 13,
dim 15q22qter
26 f 86 SS IIIb 48 1 A dim 17p10pter
27 m 71 LCA30 IIb þ 18 4 A enh 7q31pter,
enh 17q11qter
dim 9q22q31,
dim 17p10pter
28 f 67 CTCL
CD8þ
IVb 23 7 A enh 3p22pter,
enh 6q14q16, enh X
dim 4q21q24, dim 6q25qter,
dim 10p11.2pter,
dim 13q22qter
29 m 82 SS IVa þ 7 9 A enh 6p22pter,
enh 8q10qter, enh 10p12pter,
enh 17q11.1q23
dim 8p10pter,
dim 11q11q23,
dim 18p11.1p11.3,
dim 19p13.3, dim 20q10qter
30 f 60 SS IVb 24 11 A enh 3q10q13, enh 4,
enh 7, enh 8q10qter,
enh 20q10qter
dim 6q13qter, dim 9p10pter,
dim 10p11.2q21, dim 13,
dim 16q24, dim 17p13
31 f 87 SS IVb 27 12 A enh 8, enh 10p13pter,
enh 17q11q22,
enh Xp21q21
dim 2p21pter,
dim 2q34qter, dim 5q21q23,
dim 10q10qter,
dim 11p10pter, dim 12,
dim 13q22pter,
dim 17p10pter
32 m 67 LCA30 IVb 32 19 A enh 1q10qter, enh 2,
enh 5q23q31, enh 6q21q22,
enh 7, enh 8q10qter,
enh 12p10pter
dim 3, dim 6q10q16,
dim 6q22qter,
dim 10q24qter, dim 13,
dim 16, dim 17p10pter,
dim 18, dim 19p13.2pter,
dim 20, dim 21q22qter, dim Y
No, patient number; m, male; f, female; age, age at onset; LCA, large cell anaplastic; LCP, large cell pleomorphic; CI, chromosomal imbalances; group,
disease group according to EORTC criteria; I, indolent; A, aggressive; dim, diminished chromatin; enh, enhanced chromatin.
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Discussion
The information on chromosomal aberrations in CTCL is
remarkably scarce when compared with other neoplasms,
in particular with other lymphomas/leukemias. In this study,
a sample of clinically and histopathologically well-defined
patients was analyzed for chromosomal imbalances using
CGH. The copy number changes were related to the clinical
course of the disease.
Published data for CTCL report a lower percentage of
aberrations than found for patients in this study. Also for
other lymphomas (e.g., ATL) (Tsukasaki et al, 2001), a higher
frequency of alterations is detected by CGH than found with
conventional methods.
Most reports are based on G-banding (Erkman-Balis and
Rappaport, 1974; Whang-Peng et al, 1979; Johnson et al,
1985; Barbieri et al, 1986; Berrebi et al, 1989). For example,
a recent large study on chromosomal aberrations in CTCL
using conventional cytogenetic methods has described
aberrations in 11 of 19 patients (58%) (Thangavelu et al,
1997). In the present CGH study, imbalances were found in
21 of 32 patients (66%), despite the fact that CGH does not
detect balanced translocations, which are the most com-
mon chromosome alterations in lymphoma.
Figure 1
Results of the CGH analysis of 32 patients with indolent and
aggressive CTCL. (a) Lines on the left of the chromosome ideograms
indicate loss of a chromosomal region in a patient (diminished
chromatin), and lines on the right side represent gains (enhanced
chromatin). (b) Box chart of aberrations for the long and short
chromosomal arms in the 32 patients. Red¼ loss of chromatin,
green¼gain of chromatin, yellow¼ loss and gain of chromatin.
Figure 2
Correlation of the number of CI with the clinical tumor stage. Each
circle represents the number of CI in a patient; the bar represents the
mean number of CI.
Figure3
Calculated survival curves for CTCL patients using the Kaplan–
Meier method. (a) The survival of patients in early stages (Ia–IIa) was
significantly better than in advanced stages (IIb–IVb). (b) A high number
of CI (X5) was associated with shorter survival.
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In summary, although CGH does not detect inversions
and balanced translocations that are found by G-banding
studies, the overall number of detected aberrations is higher
using CGH than reported for conventional cytogenetics.
To date, two studies investigating patients with CTCL by
using CGH have been published (Karenko et al, 1999;
Mao et al, 2002). In a study by Karenko et al (1999),
chromosomal aberrations were reported in six patients with
SS, whereas four patients with MF were devoid of im-
balances. In contrast, in our series nine of 19 patients with
MF showed chromosomal aberrations. On the other hand,
of the lymphoma subtypes studied here, only in the case of
MF and in one case with LCA 30þ there were examples
without chromosomal alterations.
In a study by Mao et al (2002), chromosomal imbalances
were seen in 19 of 34 patients (56%).
In addition, one case report of a patient with Se´zary
syndrome investigated by CGH has been published (So
et al, 2000), which showed euchromatin gain.
Some of the CGH findings of this study confirm reports
from earlier conventional cytogenetic studies. The most
striking agreement between G-banding studies (Thangavelu
et al, 1997) and CGH studies (Karenko et al, 1999) are gains
in 8q, and losses of 10q and 17p. Losses in 10q and 17p
were also found in the recent study of Mao et al (2002).
Aberrations of the chromosome 10q region have, in addition
to CTCL (Berger and Bernheim, 1987; Schlegelberger et al,
1994; Thangavelu et al, 1997), been reported for other
hematological malignancies, including acute T cell leuke-
mias (Park et al, 1992), B cell lymphomas (Siebert et al,
1998), and other non-Hodgkin lymphomas (Speaks et al,
1992). This region encodes tumor suppressor genes
such as PTEN (10q23.3), MXI1 (10q25–26), and DMBT1
(10q25–26).
Losses of 17p are among the most frequent aberrations
in neoplastic disorders of epithelial (Hoff et al, 2001) and
mesenchymal origin (Nishio et al, 2002). Recently it became
clear that losses of the short arm of chromosome 17 occur
as late secondary aberrations in carcinomas (Herrington
et al, 2001; Hoff et al, 2001; Yeh et al, 2001). 17p losses
were also reported for leukemias (Joos et al, 2002), and a
role of this aberration as a prognostic indicator for B cell
non-Hodgkin lymphoma (Stokke et al, 2001) is being con-
sidered. For CTCL, conventional cytogenetics (Limon et al,
1995; Thangavelu et al, 1997) and previous CGH studies
(Karenko et al, 1999; Mao et al, 2002) found 17p losses with
frequencies comparable to the present study. In contrast to
other leukemias (Chevallier et al, 2002) and lymphomas
(Stokke et al, 2001), in the CTCL patient sample of this
study no correlation with the clinical course of the disease
and, thus, no predictive value of this aberration was seen.
Well-known tumor suppressor genes such as tumor protein
53 (P53; 17p13.1) and CT-10 regulator of kinase (CRK;
17p13.1) are encoded in this region. Similar to our
chromosomal findings, a study of P53 expression in CTCL
did not find a correlation with prognosis (van Haselen et al,
1997).
Losses in 13q are a consistent finding of G-banding
(Thangavelu et al, 1997) and of an earlier CGH study
(Karenko et al, 1999), whereas the recent study of Mao et al
(2002) did not observe this aberration. At present, only
oncogenes that have not been associated with leukemic
diseases, such as the retinoblastoma oncogene RB-1
(13q14.1–14.2) or the breast cancer type 3 oncogene
BRCA3 (13q21), have been identified in this chromosomal
region. In our study, chromosome 13q losses were
correlated with a short survival of the patients, indicating
that genes located in this region may be pathogenetically
relevant.
Gains of chromosome 8q have been reported in a CGH
study of CTCL (Karenko et al, 1999), as well as for B cell
lymphomas (Monni et al, 1996; Dierlamm et al, 1997), but
have been detected rarely in the CTLC study of Mao et al
(2002). Several oncogenes are located on the long arm of
chromosome 8, including MYC, MYC activator oncogene
PVT1 (both 8q24), and MOS (8q22). These oncogenes are
affected by translocations involving the regions coding for the
immunoglobulin chain on chromosomes 2, 14, or 22. Their
pathogenetic role in CTCL remains unresolved at present.
Among the most prominent aberrations detected in this
study are gains of chromosome 7. To date, cytogenetic
studies for T cell lymphomas rarely described aberrations of
chromosome 7 (Lepretre et al, 2000), maybe because the
information on chromosomal aberrations for T cell lympho-
mas is rather scarce as compared to B cell lymphomas. In a
CTLC cell line, a persistent trisomy of chromosome 7 has
been reported (Bagot et al, 1998). These observations may
Figure 4
Comparison of indolent and aggressive forms of CTCL. (a) The
average number of CI was significantly higher in aggressive forms
(po0.05). (b) In aggressive forms, gains occurred more frequently than
losses (po0.05). (c) The calculated survival rate was significantly
shorter in aggressive forms of CTLC.
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be of particular relevance to T cell lymphomas, because
genes encoding T cell receptor chains (g: 7p15; b: 7q32–35)
are located on this chromosome. Possibly the gains are a
consequence of the naturally occurring high rate of
recombinations and variations at this locus. In a study on
ATL, this aberration correlated with a better prognosis for
the clinical course of the disease (Tsukasaki et al, 2001). In
contrast in CTCL, gains in chromosome 7 do not correlate
Figure 5
Correlation of CI with cumulative survival rates. Gain of chromatin in 8q and loss of chromatin in 6q, 10q, and 13q correlated with a significantly
shorter survival. Loss in 17p and gain in 7 did not influence the prognosis of the disease.
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with a better survival. The survival of these patients appears
to be shorter, which, however, because of the limited
number of patients and mosaicisms, is not statistically signi-
ficant. Further studies using fluorescence in situ hybridiza-
tion (FISH) will be required to determine the pathogenetic
role of this region/chromosome and possible candidate
genes for tumor progression. All CI mentioned above were
also detected in early stages of the disease, suggesting that
these aberrations are involved in tumor development and
progression.
Specific combinations of CI appear as a characteristic
pattern not described previously. In fact, the most common
combinatorial CI (enh 7þdim 13q and dim 6qþ enh 7þ enh
8qþdim 13q) occurred in a substantial number (24%) of
patients with aberrations.
There are aberrations that had been described from
earlier studies, but were not detected in the present study.
These alterations include complete or allelic losses of the
short arms of chromosomes 1p and 9q (Thangavelu et al,
1997; Scarisbrick et al, 2001; Mao et al, 2002). Technical
reasons may account for these differences, since in an
earlier CGH study these regions were also not detected
(Karenko et al, 1999). Moreover, the clinical variability of
CTCL is likely to contribute to unequivocal results in these
regions.
In summary, the present study is the first to combine the
analysis of a large sample of CTCL patients by comparative
genomic hybridization with survival rates of the patients.
Several chromosomal aberrations were found in CTCL that
also occur in a broad spectrum of other neoplasias (e.g.,
10q and 17p). CI that occur more specifically in CTCL (6q, 7,
8q, and 13q) were found as a characteristic combination.
Materials and Methods
Patients Thirty-two patients (12 women, 20 men) with a mean age
of 66.4  11.7 y (mean  SD) from the Department of Dermatol-
ogy, Charite´ School of Medicine, Berlin, Germany, were included
after informed consent. This study was performed in compliance
with the Declaration of Helsinki Guidelines. CTCL were diagnosed
by clinical examination, as well as by histological and immunohis-
tochemical analysis of skin biopsies and of peripheral blood
samples. In all cases, molecular studies of clonal T cell expansion
were performed using PCR for the gamma chain of the T cell
receptor (TCR). EORTC criteria were used for the classification of
the disease. To correlate the cytogenetic findings with the clinical
course of the disease, patients were assigned to two main groups,
indolent and aggressive, according to EORTC criteria (Willemze et
al, 1997). For disease staging, the TNM criteria (tumor, node,
metastasis) were applied (Bunn and Lamberg, 1979). The patient
data are summarized in Table I. All samples analyzed in this study
were taken before therapy, such as systemic chemotherapy and/or
immunotherapy.
CGH Test DNA was isolated from skin tumor samples using
standard methods. Briefly, genomic DNAs were differently labeled
by nick translation with SpectrumGreen-dUTP (VYSIS, Downers
Grove, Illinois; test DNA) and SpectrumOrange-dUTP (VYSIS;
normal reference DNA) using commercially available nick transla-
tion systems (VYSIS). Target metaphase spreads were prepared
from PHA-stimulated peripheral blood lymphocytes from a
karyotypically normal male and pre-treated prior to hybridization
according to standard FISH protocols. For each hybridization, 200
ng of labeled test DNA, 200 ng reference DNA, and 12.5 mg Cot-1
DNA were coprecipitated, resuspended in 14 mL hybridization mix
containing 50% formamide, 2  SSC and 10% dextran sulfate,
denaturated at 701C for 5 min, and hybridized to denatured
metaphase spreads (To¨nnies et al, 2001). Slides were incubated at
371C in a moist chamber for 2 d. Post-hybridization washes were
performed as described by Kallioniemi et al (1994). Images of the
hybridized metaphases were evaluated using an epifluorescence
microscope (Axiophot, ZEISS, Oberkochen, Germany) fitted with
different single band pass filter sets for DAPI, Spectrum Green and
Spectrum Orange fluorescence. The microscope was equipped
with a cooled CCD camera (Hamamatsu, Bridgewater, New Jersey)
for image acquisition. Image analysis and karyotyping (CGH) was
performed using the ISIS analysis system (MetaSystems, Altlus-
sheim, Germany). Diagnostic thresholds used for the identification
of chromosomal under-representations (deletions) and over-repre-
sentations (duplications) were 0.85 and 1.17 (Larramendy et al,
1998).
Statistical analysis The data are expressed as means  standard
error of the mean (SEM). For comparison of means, the Mann–
Whitney U test was applied. Estimated survival curves, five years
survival, and median survival time (MST) were calculated according
to the Kaplan–Meier method (KM) and compared by using the log-
rank test.
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